Penpulimab (Anniko)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 13:20, 30 September 2022 by Jwarner (talk | contribs) (Created page with "'''Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.''' ==Mechanism of action== PD-1 inhibitor ==Diseases for which it is used== *...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.

Mechanism of action

PD-1 inhibitor

Diseases for which it is used

History of changes in NPMA indication

  • 8/5/2021: Approved for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment.

Also known as

  • Code name: AK105
Retrieved from "https://hemonc.org/w/index.php?title=Penpulimab_(Anniko)&oldid=62447"